Skip to Main Content

CAMBRIDGE, Mass. — As more pivotal clinical trials for microbiome-based therapies begin, some people are already asking where these drugs might go next.

One set of experts speaking at MassBio’s annual meeting on Thursday thought they had the answer — actually, two answers.  

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!